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Background. Numerous medications are known to be associated with the development of lower urinary tract symptoms (LUTS).
One such medication group is calcium channel blockers (CCB). Objective. To critically examine the literature regarding the
involvement of CCB in manifestation of LUTS in humans. Methods. A systematic literature search was conducted on PubMed,
SciELO, Scopus, and OpenGrey databases to find all potentially relevant research studies before August 2016. Results. Five studies
met the inclusion criteria and were included in this review. Three out of five studies stated that CCB were involved in either
precipitation or exacerbation of LUTS. As for the remaining two studies, one study found out that only the monotherapy of CCB
was associated with increased prevalence of nocturia and voiding symptoms in young females, whereas the other study reported
an inverse association of CCB with LUTS. The methodological quality of studies was considered high for four studies and low for
one study. Conclusion. Healthcare providers should make efforts for an earlier identification of the individuals at risk of LUTS prior
to the commencement of CCB therapy. Moreover, patients should be counselled to notify their healthcare provider if they notice
urinary symptoms after the initiation of CCB.
1. Introduction
Lower urinary tract symptoms (LUTS) is an umbrella term
that was first coined in 1994 to disassociate urinary symptoms
in male from any implied specific site of origin of the symp-
toms, such as prostate [1]. LUTS encompasses all urinary
symptoms, namely, voiding, storage, and postvoiding [2],
and this term corroborates well with the earlier classification
proposed byWein [3, 4] who suggested that urinary disorders
would be more elegantly characterized as “failure to store”
or “failure to empty.” These symptoms are common and
troublesome and have a negative impact on patients’ quality
of life (QOL). LUTS are considered to be progressive, age-
related, non-gender-specific, non-organ-specific group of
symptoms [2] and have been associatedwith various diseases,
surgeries, and medications. One such medication group is
calcium channel blockers (CCB) as the blockade of L-type
calcium channels in detrusor muscles not only inhibits the
bladder contraction [5–7], but also increases the duration to
reach maximal bladder pressure and reduces maximal power
of contraction, maximal rate of emptying, and rate of bladder
filling which may lead to polyuria, micturition frequency,
micturition disorder, and nocturia [8].
The current review was conducted to answer the question
“Is there a significant relationship between the use of CCB
and manifestation of LUTS in humans?” This review may
help the healthcare providers in appropriate selection of CCB
having minimal or no urological effects.
2. Methodology
2.1. Administrative Information. For the current systematic
review, we followed the protocols and checklist of Providing
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Figure 1: Flow diagram of the identification of the studies for inclusion in the systematic review.
Innovative Service Models and Assessment (PRISMA) [9]
and PRISMA-Protocol 2015 [10, 11]. We were not able to
conduct meta-analysis due to wide diversity in the studies
reporting association of CCB with LUTS. Therefore, the
articles were analyzed descriptively.
2.2. Study Selection. A systematic literature search was con-
ducted by two investigators (MS andNS) onPubMed, Scopus,
Scientific Electronic Library Online (SciELO), and Open-
Grey databases to find all potentially relevant publications
before August 2016. The following categories of words/terms
and their synonyms were used: calcium channel blockers,
antihypertensive drugs, lower urinary tract synonyms, and
urination disorders. The reference lists of screened publica-
tions were also checked to identify further relevant studies.
Moreover, if required, corresponding authors of the included
studies were also contacted through email.
2.3. Inclusion andExclusionCriteria. All the original research
articles that evaluated the association between calcium chan-
nel blockers and lower urinary tract symptoms in adults (>18
years) were included in this review. Literature reviews, edi-
torials, commentaries, case reports, and conference abstracts
were excluded, as were the studies with patients on medica-
tions other than calcium channel blockers and patients <18
years of age and studies published in a language other than
English.
2.4. Data Extraction. After eliminating duplicates, two inves-
tigators (MS and NS) reviewed each article independently.
Discrepancies were discussed and agreement was achieved
by consensus and opinion of a third investigator (AHK) was
requested where necessary. The full-text of all articles which
met the inclusion criteria was obtained. Relevant data were
extracted and tabulated.
2.5. Quality Assessment. In the current review, the quality of
included studies was assessed independently by two investi-
gators (MS and KH) using Newcastle-Ottawa scale (NOS) for
cohort studies [12] and a modified version for cross-sectional
studies developed by Herzog et al. [13]. Newcastle-Ottawa
scale consists of 3 parameters of quality: selection (4 points
for cohort studies and 5 points for cross-sectional studies),
comparability (2 points), and outcome assessment (3 points).
Studies with scores of ≥7 were considered as high quality
studies and of 5-6 as moderate quality [14].
2.6. Case Definition. In the current review, LUTS encompass
all voiding (weak stream, splitting or spraying, intermittency,
hesitancy, straining, and terminal dribble), storage (increased
daytime urinary frequency, nocturia, urgency to urinate, and
urinary incontinence), and postmicturition symptoms (sen-
sation of incomplete bladder emptying and postmicturition
dribbling) [2].
3. Results
3.1. Search Results. As depicted in Figure 1, we identified two
thousand and twenty-three studies. After removing the dupli-
cates and after exclusion of studies based on the examination
of the titles and abstracts, fifteen studies were selected for
the review of the full-text. After the detailed evaluation of
fifteen articles, 5 studies were included in the final review.
Among the 10 excluded studies, 3 had no outcome of interest,
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medications, one study reported the prevalence of commonly
prescribed medications potentially contributing to urinary
symptoms among geriatrics seeking care for incontinence,
one study was published from Elhebir dissertation [16], and
one dissertation from which the manuscripts of Hughes et al.
was published [15].
3.2. Study Characteristics. Characteristics of the included
studies are shown in Table 1. All the studies were published
in the last eight years (oldest in 2009 and latest in 2013). Of
the five included studies, two were conducted in Australia
[15, 16] whereas the rest of the studies were conducted in the
USA [17], Japan [18], and Netherlands [19]. The number of
study population ranged from 38 to 3790, withmajority of the
studies (3/5) involving onlymales [15, 18, 19].Three out of five
studies were undertaken on individuals aged >40 years [15,
16, 19], whereas one study [17] included individuals ranging
from 30 to 79 years of age and one study did not specify
the criterion of age [18]. International prostate symptom
score was the predominantly used research tool to assess the
frequency and severity of LUTS [15, 16, 18, 19]. Only one study
used the American Urological Association-Symptom Index
for the evaluation of LUTS [17].
3.3. Association of Calcium Channel Blockers with Lower
Urinary Tract Symptoms. Therelationship ofCCBwith LUTS
is shown inTable 2.Thenumber ofCCB-users varied between
the studies [minimum 38 and maximum 207 (54 on CCB
monotherapy and 153 on CCB and other antihypertensive
drugs)]. Of all the included studies, two studies [15, 16]
reported the types of CCB that were evaluated for their
association with LUTS. Three out of five studies [15, 16, 18]
reported a significant association of CCB use with LUTS
whereas one study [17] reported that only monotherapy of
CCB was associated with increased prevalence of nocturia
and voiding symptoms in females <55 years old whereas
no significant relationship was found in CCB use among
males. On the contrary, one study [19] reported an inverse
association of CCB use with LUTS.
3.4. Impact of Calcium Channel Blockers-Related Lower Uri-
nary Tract Symptoms on the Quality of Life. As shown in
Table 2, 2 out of 5 studies did not assess the impact of CCB-
related LUTS on the QOL [17, 19]. Hughes et al. reported
a significant increase in the mean QOL score after CCB
commencement [15]. This finding indicated a significant
reduction in the individuals’ QOL after CCB therapy as the
overall inconvenience to participants caused by their current
urinary tract symptoms (IPSS-QOL index) was obtained by
scoring from 0 (delighted) to 6 (terrible). Moreover, Elhebir
also revealed that non-CCB-users had better QOL thanCCB-
users [16]. By contrast, one study reported that there was no
significant difference in the QOL among individuals on CCB
therapy and untreated hypertensives [18].
3.5. Quality Assessment. The quality assessment of studies
using NOS is shown in Table 3. The qualities of studies were
considered high for four studies [16–19] and low for one study
[15].
4. Discussion and Interpretation
This systematic review was sought to examine the association
of CCB with LUTS in humans and the impact of this
association on patients’ QOL. Despite a high prevalence of
hypertension (40% in adults aged ≥25 years [20]) worldwide
and a significantly high use of CCB, data regarding the
association of CCB use with LUTS and their impact on
individuals QOL is sparse as we were able to identify only five
studies that met the inclusion criteria. Among the included
studies, three reported a significant relationship between
CCB use and LUTS [15, 16, 18] whereas, in the remaining two
studies, one study [17] reported that monotherapy of CCB
was linked with higher prevalence of nocturia and voiding
symptoms in only young females and the other study [19]
reported the inverse association of CCB use with LUTS. Of
three studies that reported the association of CCBwith LUTS,
one study [15] had a very small sample size (𝑁 = 38 males)
to show any differences in CCB subclass [dihydropyridines
(DHP) versus nondihydropyridines (NDHP)] effects or any
differences in the effects of individual CCB within the
subclasses, and the outcome depended on participants’ recall
of their urinary symptoms before the initiation of CCB
therapy, which in some cases (39.5%) was greater than 5 years
earlier. Moreover, 18 out of the 38 participants had medical
conditions (stroke, spinal disc disorders, congestive heart
failure, impairedmobility, recurrent cough, and transurethral
resection of the prostate) that potentially contribute to
LUTS.Another study that demonstrated a significant increase
in the mean IPSS score in CCB-users as compared to
untreated hypertensives did not describe the types of CCB
(DHP or NDHP, monotherapy or CCB combination with
other antihypertensive agents, and the individual CCB) [18].
Interestingly, this study reported that angiotensin receptor
blockers may have the potential to improve LUTS in men.
Only the study conducted by Elhebir [16] demonstrated the
impact of NDHP (diltiazem and verapamil), highly vascular
selective DHP (felodipine and lercanidipine), and other DHP
(amlodipine and nifedipine) on LUTS. They reported that
felodipine and lercanidipine were not associated with LUTS,
whereas amlodipine, nifedipine, diltiazem, and verapamil
were found to have significant association with severe as well
asmoderate-severe LUTS.Moreover, they also reported that a
significantly higher number of CCB-users in their study were
found to be taking medications for their urinary symptoms
(22.4% versus 9.3%, 𝑝 = 0.003) and have had urogenital
surgeries compared to the non-CCB-users (16.5% versus
7.8%, 𝑝 = 0.029). These findings demonstrated the extra
burden on these patients as well as their families. The impact
of theCCB induced LUTS on patients’ QOLwas controversial
as the findings of Ito et al. [18] were contradicting to the
findings of Hughes et al. [15] and Elhebir [16] reporting
the significant worsening in the patients’ QOL due to the
precipitation and exacerbation of LUTS due to CCB.
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Table 3: Study quality assessment using Newcastle-Ottawa scale.
Study [ref] year Selection Comparability Outcome Total score
Hughes et al. [15] 2011 ∗ ∗∗ ∗ 4
Elhebir [16] 2011 ∗ ∗ ∗ ∗ ∗ ∗∗ ∗∗ 9
Hall et al. [17] 2012 ∗ ∗ ∗∗ ∗∗ ∗∗ 8
Ito et al. [18] 2013 ∗ ∗ ∗∗ ∗∗ ∗∗ 8
Kok et al. [19] 2009 ∗ ∗ ∗ ∗ ∗ ∗∗ ∗∗ 9
5. Limitations
Though all possible efforts were made to warrant the inclu-
sion of all potentially relevant research studies in this review,
unintentional selection biasness might still be present. Fur-
thermore, our literature search yielded 2023 publications and
only five were deemed appropriate for the inclusion in the
review, not enough for formal quantitative meta-analysis.
The association of CCB with LUTS was not the primary
objective in some of the selected studies and the majority of
the included studies did not specify the types of CCB.
6. Recommendations
Due to the advancement in clinical research, many new CCB
medications are now available in the market. These medica-
tions contain CCB combination with other drugs (diuretics,
angiotensin enzyme inhibitors, angiotensin receptor block-
ers, statins, etc.).Thefindings of the current systematic review
warrant further investigations using a large sample size to
explore the effect of CCB in precipitation and exacerbation of
LUTS (DHP versus NDHP, CCB monotherapy versus CCB
combination therapy, and effects of individual CCB within
the subclasses on LUTS).
7. Conclusion
The findings of the present review indicated that despite the
extensive CCB use to treat various cardiovascular diseases
worldwide, there is limited data concerning the association
of these agents with urinary symptoms. However, further
studies are required to provide concrete evidence about the
said association and its impact on patients’ QOL. Healthcare
providers should make efforts for an early identification of
the individuals at risk of LUTS prior to the commencement
of CCB therapy. Moreover, patients should be counselled
to notify their healthcare provider if they notice urinary
symptoms after the initiation of CCB therapy.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
References
[1] P. Abrams, “New words for old: Lower urinary tract symptoms
for “prostatism”,” British Medical Journal, vol. 308, no. 6934, pp.
929-930, 1994.
[2] C. R. Chapple, A. J. Wein, P. Abrams et al., “Lower urinary tract
symptoms revisited: a broader clinical perspective,” European
Urology, vol. 54, no. 3, pp. 563–569, 2008.
[3] A. J. Wein, “Classification of neurogenic voiding dysfunction,”
The Journal of Urology, vol. 125, no. 5, pp. 605–609, 1981.
[4] A. J. Wein, “Pathophysiology and classification of voiding
dysfunction,” in Campbell-Walsh Urology, A. J. Wein, L. R.
Kavoussi, A. C. Novick, A. W. Partin, and C. A. Peters, Eds., pp.
1973–1985, Saunders/Elsevier, Philadelphia, Penn, USA, 2007.
[5] J. W. Wegener, V. Schulla, T.-S. Lee et al., “An essential role of
Cav1.2 L-type calcium channel for urinary bladder function,”
The FASEB Journal, vol. 18, no. 10, pp. 1159–1161, 2004.
[6] V. C. Lowe and L. Noronha-Blob, “Effect of extracellular Ca2+
on cholinergic, KCl and phorbol ester-mediated phosphoinosi-
tide turnover and guinea pig urinary bladder contraction,”
European Journal of Pharmacology, vol. 195, no. 2, pp. 273–279,
1991.
[7] K. Hamada, Y. Sasaki, N. Taniguchi et al., “Anticholinergic
and calcium antagonistic activities of NS-21 contribute to
the inhibition of rat urinary bladder contractions,” General
Pharmacology: The Vascular System, vol. 29, no. 5, pp. 771–778,
1997.
[8] G. Horva´th, Z.Morvay,M. Kova´cs, A. Szila´gyi, andM. Szikszay,
“Drugs acting on calcium channels modulate the diuretic and
micturition effects of dexmedetomidine in rats,” Life Sciences,
vol. 59, no. 15, pp. 1247–1257, 1996.
[9] A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA
statement for reporting systematic reviews and meta-analyses
of studies that evaluate health care interventions: explanation
and elaboration,” Annals of Internal Medicine, vol. 151, no. 4, pp.
65–94, 2009.
[10] D. Moher, L. Shamseer, and M. Clarke, “Preferred report-
ing items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement,” Systematic Reviews, vol. 4, no. 1,
article 1, 2015.
[11] L. Shamseer, D. Moher, M. Clarke et al., “Preferred report-
ing items for systematic review and meta-analysis protocols
(prisma-p) 2015: Elaboration and explanation,” British Medical
Journal, vol. 349, article g7647, 2015.
[12] G. A. Wells, B. Shea, D. O’Connell et al.,The Newcastle-Ottawa
Scale (NOS) for Assessing the Quality of Nonrandomised Studies
in Meta-Analyses, Ottawa Health Research Institute, Ottawa,
Canada, 2011, Available at: http://www.ohri.ca/programs/
clinical epidemiology/oxford.asp.
[13] R. Herzog, M. J. A´lvarez-Pasquin, C. Dı´az, J. L. Del Barrio, J.
M. Estrada, and A´. Gil, “Are healthcare workers intentions to
vaccinate related to their knowledge, beliefs and attitudes? A
systematic review,” BMCPublic Health, vol. 13, no. 1, pp. 113–154,
2013.
[14] A. V. Hernandez, V. Pasupuleti, V. A. Benites-Zapata, P. Thota,
A. Deshpande, and F. R. Perez-Lopez, “Insulin resistance
BioMed Research International 7
and endometrial cancer risk: A systematic review and meta-
analysis,” European Journal of Cancer, vol. 51, no. 18, pp. 2747–
2758, 2015.
[15] J. D. Hughes, M. A. Coles, and A. Joyce, “Calcium channel
blocker associated lower urinary tract symptoms in males:
An Australian retrospective observational study,” Quality in
Primary Care, vol. 19, no. 4, pp. 223–231, 2011.
[16] E. S. Elhebir, Calcium Antagonists-Induced Lower Urinary Tract
Symptoms [Doctor of Philosophy], Curtin University of Technol-
ogy, Perth, Western Australia, May 2011.
[17] S. A. Hall, G. R. Chiu, D. W. Kaufman, G. A. Wittert, C. L.
Link, and J. B. McKinlay, “Commonly used antihypertensives
and lower urinary tract symptoms: Results from the Boston
Area Community Health (BACH) Survey,” BJU International,
vol. 109, no. 11, pp. 1676–1684, 2012.
[18] H. Ito, M. Taga, K. Tsuchiyama, H. Akino, and O. Yokoyama,
“IPSS is lower in hypertensive patients treatedwith angiotensin-
II receptor blocker: Posthoc analyses of a lower urinary tract
symptoms population,”Neurourology and Urodynamics, vol. 32,
no. 1, pp. 70–74, 2013.
[19] E. T. Kok, B.W. Schouten,A.M. Bohnen, F. P.M.W.Groeneveld,
S.Thomas, and J. L. H. R. Bosch, “Risk factors for lower urinary
tract symptoms suggestive of benign prostatic hyperplasia in
a community based population of healthy aging men: the
krimpen study,” The Journal of Urology, vol. 181, no. 2, pp. 710–
716, 2009.
[20] World Health Organization. Global Health Observatory
(GHO), Raised Blood Pressure. Situations and trends. Availabe
from: http://www.who.int/gho/ncd/risk factors/blood pres-
sure prevalence text/en/.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
